Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

T-cell–redirecting bispecific antibodies in multiple myeloma: a revolution?
Philippe Moreau, Cyrille Touzeau
Blood (2022) Vol. 139, Iss. 26, pp. 3681-3687
Open Access | Times Cited: 34

Showing 1-25 of 34 citing articles:

Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel
Noopur Raje, Kenneth C. Anderson, Hermann Einsele, et al.
Blood Cancer Journal (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 82
Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies
Antonio Tapia‐Galisteo, Luís Álvarez-Vallina, Laura Sanz
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 57
Acquired resistance to a GPRC5D-directed T-cell engager in multiple myeloma is mediated by genetic or epigenetic target inactivation
Jennifer Derrien, Sarah Gastineau, Antoine Frigout, et al.
Nature Cancer (2023) Vol. 4, Iss. 11, pp. 1536-1543
Open Access | Times Cited: 42
Functional cure and long-term survival in multiple myeloma: how to challenge the previously impossible
Monika Engelhardt, K. Martin Kortüm, Hartmut Goldschmidt, et al.
Haematologica (2024)
Open Access | Times Cited: 14
Comprehensive Review of Early and Late Toxicities in CAR T-Cell Therapy and Bispecific Antibody Treatments for Hematologic Malignancies
Ayrton Bangolo, Behzad Amoozgar, Charlene Mansour, et al.
Cancers (2025) Vol. 17, Iss. 2, pp. 282-282
Open Access | Times Cited: 1
Targeting cereblon in hematologic malignancies
Ota Fuchs
Blood Reviews (2022) Vol. 57, pp. 100994-100994
Open Access | Times Cited: 31
Bispecific Antibodies in Hematological Malignancies: A Scoping Review
Mohamed H. Omer, Areez Shafqat, Omar Ahmad, et al.
Cancers (2023) Vol. 15, Iss. 18, pp. 4550-4550
Open Access | Times Cited: 17
Mechanisms of resistance to bispecific T cell engagers in multiple myeloma and their clinical implications
Éric Letouzé, Philippe Moreau, Nikhil Munshi, et al.
Blood Advances (2024) Vol. 8, Iss. 11, pp. 2952-2959
Open Access | Times Cited: 8
Development of ISB 1442, a CD38 and CD47 bispecific biparatopic antibody innate cell modulator for the treatment of multiple myeloma
Camille Grandclément, C. Estoppey, E. Dheilly, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 7
Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma: Results of the Compassionate Use or the Expanded Access Program in Spain
Javier de la Rubia, Rafael Alonso, María Esther Clavero, et al.
Cancers (2023) Vol. 15, Iss. 11, pp. 2964-2964
Open Access | Times Cited: 12
Bispecific Antibodies in the Treatment of Multiple Myeloma
Xiang Zhou, Xianghui Xiao, K. Martin Kortuem, et al.
Hematology/Oncology Clinics of North America (2024) Vol. 38, Iss. 2, pp. 361-381
Closed Access | Times Cited: 4
Targeting GPRC5D in multiple myeloma
Shatha Elemian, Samer Al Hadidi
Expert Review of Anticancer Therapy (2024) Vol. 24, Iss. 5, pp. 229-238
Closed Access | Times Cited: 4
T-Cell Redirecting Therapies in Multiple Myeloma: Pathogenesis and Management of Toxicities Beyond CRS and ICANS
Katia Mancuso, Marco Talarico, Enrica Manzato, et al.
Cancers (2025) Vol. 17, Iss. 9, pp. 1514-1514
Open Access
Current status of bispecific antibodies and CAR-T therapies in multiple myeloma
Wojciech Szlasa, Jarosław Dybko
International Immunopharmacology (2024) Vol. 134, pp. 112043-112043
Closed Access | Times Cited: 3
New Developments in Myeloma Treatment and Response Assessment
Françoise Kraeber‐Bodéré, Bastien Jamet, Davide Bezzi, et al.
Journal of Nuclear Medicine (2023) Vol. 64, Iss. 9, pp. 1331-1343
Open Access | Times Cited: 9
2-[18F]FDG PET/CT Flare-up Phenomena Following T-Cell Engager Bispecific Antibody in Multiple Myeloma
Bastien Jamet, Caroline Bodet‐Milin, Philippe Moreau, et al.
Clinical Nuclear Medicine (2023) Vol. 48, Iss. 5, pp. e230-e231
Closed Access | Times Cited: 8
Elranatamab: a new promising BispAb in multiple myeloma treatment
Sebastian Grosicki, Martyna Bednarczyk, Karolina Kociszewska
Expert Review of Anticancer Therapy (2023) Vol. 23, Iss. 8, pp. 775-782
Closed Access | Times Cited: 8
Efficacy and safety of bispecific antibodies therapy for relapsed or refractory multiple myeloma: a systematic review and meta-analysis of prospective clinical trials
Xin Wang, Ailin Zhao, Jinbing Zhu, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 3
T cell redirecting bispecific antibodies for multiple myeloma: emerging therapeutic strategies in a changing treatment landscape
Dickran Kazandjian, Andrew S. Kowalski, Ola Landgren
Leukemia & lymphoma/Leukemia and lymphoma (2022) Vol. 63, Iss. 13, pp. 3032-3043
Open Access | Times Cited: 14
Pre-Clinical Assessment of SAR442257, a CD38/CD3xCD28 Trispecific T Cell Engager in Treatment of Relapsed/Refractory Multiple Myeloma
Anna Luise Grab, Peter Kim, Lukas John, et al.
Cells (2024) Vol. 13, Iss. 10, pp. 879-879
Open Access | Times Cited: 2
DNA vaccines against GPRC5D synergize with PD-1 blockade to treat multiple myeloma
Praveen Neeli, Perry Ayn Mayson Maza, Dafei Chai, et al.
npj Vaccines (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 2
Bispecific antibody and chimeric antigen receptor (CAR) modified T-cell in the treatment of multiple myeloma: where do we stand today?
Xiang Zhou, K. Martin Kortuem, Leo Rasche, et al.
La Presse Médicale (2024), pp. 104265-104265
Open Access | Times Cited: 2
IMiDs Augment CD3-Bispecific Antibody–Induced CD8+ T-Cell Cytotoxicity and Expansion by Enhancing IL2 Production
Ji Li, Dionysos Slaga, Jennifer Johnston, et al.
Molecular Cancer Therapeutics (2023) Vol. 22, Iss. 5, pp. 659-666
Open Access | Times Cited: 5
Invariant NKT cells dictate antitumor immunity elicited by a bispecific antibody cotargeting CD3 and BCMA
Mika Casey, Cui Tu, Simon J. Harrison, et al.
Blood Advances (2022) Vol. 6, Iss. 17, pp. 5165-5170
Open Access | Times Cited: 8
Recommendations for the effective use of T-cell–redirecting therapies: a Canadian consensus statement
Guido Lancman, Kevin Song, Darrell White, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top